Journal of General Internal Medicine

, 24:226

Home Buprenorphine/Naloxone Induction in Primary Care

Authors

    • New York University School of Medicine
  • Ellie Grossman
    • New York University School of Medicine
  • Danae DiRocco
    • New York University School of Medicine
  • Marc N. Gourevitch
    • New York University School of Medicine
Original Article

DOI: 10.1007/s11606-008-0866-8

Cite this article as:
Lee, J.D., Grossman, E., DiRocco, D. et al. J GEN INTERN MED (2009) 24: 226. doi:10.1007/s11606-008-0866-8

ABSTRACT

BACKGROUND

Buprenorphine can be used for the treatment of opioid dependence in primary care settings. National guidelines recommend directly observed initial dosing followed by multiple in-clinic visits during the induction week. We offered buprenorphine treatment at a public hospital primary care clinic using a home, unobserved induction protocol.

METHODS

Participants were opioid-dependent adults eligible for office-based buprenorphine treatment. The initial physician visit included assessment, education, induction telephone support instructions, an illustrated home induction pamphlet, and a 1-week buprenorphine/naloxone prescription. Patients initiated dosing off-site at a later time. Follow-up with urine toxicology testing occurred at day 7 and thereafter at varying intervals. Primary outcomes were treatment status at week 1 and induction-related events: severe precipitated withdrawal, other buprenorphine-prompted withdrawal symptoms, prolonged unrelieved withdrawal, and serious adverse events (SAEs).

RESULTS

Patients (N = 103) were predominantly heroin users (68%), but also prescription opioid misusers (18%) and methadone maintenance patients (14%). At the end of week 1, 73% were retained, 17% provided induction data but did not return to the clinic, and 11% were lost to follow-up with no induction data available. No cases of severe precipitated withdrawal and no SAEs were observed. Five cases (5%) of mild-to-moderate buprenorphine-prompted withdrawal and eight cases of prolonged unrelieved withdrawal symptoms (8% overall, 21% of methadone-to-buprenorphine inductions) were reported. Buprenorphine-prompted withdrawal and prolonged unrelieved withdrawal symptoms were not associated with treatment status at week 1.

CONCLUSIONS

Home buprenorphine induction was feasible and appeared safe. Induction complications occurred at expected rates and were not associated with short-term treatment drop-out.

Supplementary material

11606_2008_866_MOESM1_ESM.pdf (723 kb)
Online Appendix“Burpenorphine – Beginning Treatment” (please see attached PDF) (PDF 544 KB)

Copyright information

© Society of General Internal Medicine 2008